With talquetamab-based combinations Tal-DP and Tal-D now showing efficacy at first relapse, if approved, how will you position GPRC5D-targeted bispecifics relative to BCMA-directed therapy in your treatment algorithm for relapsed/refractory MM after 1 prior line of therapy?

TL;DR: The choice between BCMA and GPRC5D will likely depend less on the efficacy data and more on prior BCMA exposure and toxicity profiles.

The phase 3 MonumenTAL-3 trial randomized patients with first or early relapsed multiple myeloma to talquetamab/daratumumab/pomalidomide (Tal-DP), talquetamab/...

I think the biggest implication of MonumenTAL data is that talquetamab may be used as bridging prior to CAR T. However, the toxicities with talquetamab - skin, nail, and most importantly taste changes/weight loss - make it a less attractive option in my eyes when you have highly effective alternativ...